RTP Mobile Logo
Virtual Consult: Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Released September 2016

Featuring interviews with Drs Robert Z Orlowski and Brad S Kahl. (Audio Content)

CE Disclosures and Faculty Information

    Taken together, it is estimated that approximately 111,410 new lymphoma and myeloma cases will be identified in the United States in the year 2016, and 33,920 individuals will die from these diseases. Importantly, more than 65 drug products are currently labeled for use in the treatment of common hematologic cancers, comprising at least 122 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    This special audio supplement to a CME satellite symposium held during the 2016 ASCO Annual Meeting uses one-to-one interviews with one leading investigator in lymphoma and one in multiple myeloma (MM) who served as faculty to discuss cases and questions submitted by attendees. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.


    • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the transplant and nontransplant settings, considering patient- and disease-related factors.
    • Appraise recent data on therapeutic advances and changing practice standards in the management of MM, and integrate this information, as appropriate, into current clinical care.
    • Appreciate the FDA approvals of novel targeted agents — ibrutinib, idelalisib, obinutuzumab and venetoclax — for the treatment of chronic lymphocytic leukemia, and discern how these therapies can be appropriately integrated into the clinical management of standard- and high-risk disease.
    • Recognize the role of novel agents in the management of indolent and aggressive lymphomas, and ensure appropriate supportive care measures to minimize side effects.
    • Incorporate new therapeutic strategies into the best-practice management of Hodgkin lymphoma.
    • Assess the ongoing clinical trials investigating innovative approaches for Hodgkin and non-Hodgkin lymphomas and MM, and refer appropriate patients for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    CME credit is no longer available for this issue

    Successful completion of this CME activity enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
    CME credit is no longer available for this issue

    This CME activity consists of an audio component. To receive credit, the participant should listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form at ResearchToPractice.com/VirtualConsult16/CME.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr OrlowskiConsulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, FORMA Therapeutics, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Spectrum Pharmaceuticals Inc, Takeda Oncology. Dr KahlAdvisory Committee: Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology; Contracted Research: Abbott Laboratories.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Janssen Biotech Inc, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: September 2016
    Expiration date: September 2017

Acknowledge and close

Listen to audio:
Virtual Consult: Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Released September 2016

Featuring interviews with Drs Robert Z Orlowski and Brad S Kahl. (Audio Content)

Read print: